NMOtion™ Blog

Discussing NMO Research and Advocacy

FDA Approves New Therapy from VielaBio for Neuromyelitis Optica Spectrum Disorder

The U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with a particular antibody (patients who are anti-aquaporin-4 or AQP4 antibody positive). NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord. Uplizna is only the second approved treatment for the disorder.

Download the press release.

Read the full press release online.

Launch Dashboard


Fast Facts about NMOSD